Using in-game win probability techniques, Stanford University researchers devised a way to better predict a cancer patient’s outcome at any point during treatment. The approach could also inform treatment decisions.
In the largest study of its kind to date, Stanford University researchers have shown that women related to a patient with a breast cancer caused by a hereditary mutation — but who don’t have the mutation themselves — have no higher risk of getting cancer than relatives of patients with other types…
Anthracyclines can be effective against breast cancer but often have toxic side effects. Stanford researchers used gene expression levels to identify women most likely to benefit from the drugs, regardless of breast cancer type or stage.
Some breast cancers return decades later. Now, a researcher at Stanford University, joined by collaborators at several other institutions, has subcategorized tumors to predict recurrence, guide treatment decisions and improve drug development.
A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.
Up to 80% of metastatic colorectal cancers are likely to have spread to distant locations in the body before the original tumor has exceeded the size of a poppy seed, according to a study of nearly 3,000 patients by researchers at the Stanford University School of Medicine.
Stanford University scientists were able to engineer immune cells known as macrophages to detect and flag cancer in mice. The researchers hope the technique can be used for early cancer diagnostics in humans.
Synthetic proteins engineered to recognize overly active biological pathways can kill cancer cells while sparing their healthy peers, according to a study by researchers at the Stanford University School of Medicine.